


PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
INFORMATION DISCLOSURE CLAIM FOR IN AN APPLICATION March 19, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
		EXAMINER Unknown		CONFIRMATION NO. Unknown	
				GROUP Unknown	



U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
mg	AE4	2003/0158221 A1	08-21-2003	Zhang <i>et al.</i>

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
mg	AQ2	WO 03/061657 A1	07-31-2003	Aryx Therapeutics		

EXAMINER <i>Michael Laffer</i>	DATE CONSIDERED 24-Mar-06
-----------------------------------	------------------------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3506.1001-002APPLICATION NO.
10/757,981INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

March 1, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR
Steven B. LandauFILING DATE
January 13, 2004EXAMINER
UnknownCONFIRMATION NO.
UnknownGROUP
Unknown

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
mb	AA	6,054,461	04-25-2000	Fairbanks <i>et al.</i>
	AB	6,117,879	09-12-2000	Fairbanks <i>et al.</i>
	AC	6,441,038 B1	08-27-2002	Loder <i>et al.</i>
	AD	6,376,550 B1	04-23-2002	Raber <i>et al.</i>
	AE	6,156,771	12-05-2000	Rubin <i>et al.</i>
	AF	6,552,045 B2	04-22-2003	Sepracor Inc.
	AG	4,783,478	11-08-1988	Wootton <i>et al.</i>
	AH	6,465,458 B1	10-15-2002	Wong <i>et al.</i>
	AI	4,695,568	09-22-1987	Ninomiya <i>et al.</i>
	AJ	2002/0107244 A1	08-08-2002	Howard, Jr.
	AK	6,355,647 B1	03-12-2002	Steiner <i>et al.</i>
	AA2	5,990,159	11-23-1999	Meulemans <i>et al.</i>
	AB2	5,962,494	10-05-1999	Young
	AC2	5,945,415	08-31-1999	Kato <i>et al.</i>
	AD2	5,663,343	09-02-1997	van der Meij <i>et al.</i>
	AE2	5,576,317	11-19-1996	Gonsalves
	AF2	5,470,868	11-28-1995	Young
	AG2	5,352,685	10-04-1994	Maruyama <i>et al.</i>
	AH2	5,225,407	07-06-1993	Oakley <i>et al.</i>
	AI2	4,939,136	07-03-1990	Haeck <i>et al.</i>
	AJ2	6,440,453 B1	08-27-2002	Fischer <i>et al.</i>
	AK2	2001/0020025 A1	09-06-2001	Megens
	AA3	2002/0002197 A1	01-03-2002	Mueller <i>et al.</i>
	AB3	2002/0086880 A1	07-04-2002	Rubin <i>et al.</i>
	AC3	2002/0086881 A1	07-04-2002	Rubin <i>et al.</i>
	AD3	4,753,789	06-28-1988	Tyers <i>et al.</i>

EXAMINER


Michael Laffer

DATE CONSIDERED

24-Mar 06

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
mb	AE3	2003/0203055 A1	10-30-2003	Rao <i>et al.</i>
	AF3	5,985,866	11-16-1999	Müller <i>et al.</i>
	AG3	5,977,127	11-02-1999	Bonnacker <i>et al.</i>
	AH3	5,530,008	06-25-1996	Azcona <i>et al.</i>
	AI3	4,845,092	07-04-1989	Sanger <i>et al.</i>
	AJ3	6,284,770 B1	09-04-2001	Mangel <i>et al.</i>
	AK3	6,429,209 B2	08-06-2002	Mangel <i>et al.</i>
	AA3	2001/0044450 A1	11-22-2001	Mangel <i>et al.</i>
	AB3	6,593,336 B2	07-15-2003	Mangel <i>et al.</i>
	AC3	2003/0036549 A1	02-20-2003	Mangel <i>et al.</i>
	AD3	2003/0036500A1	02-20-2003	Rubin <i>et al.</i>

EXAMINER 	DATE CONSIDERED 24-Mar 06
---	------------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown	

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
mb	AL +	WO 99/02516	01-25-1999	Vita-Invest, S.A.		X
	AM +	WO 02/44170 A2	06-06-2002	Vita-Invest, S.A.		
	AN +	WO 02/094249 A1	11-28-2002	Arachnova Therapeutics Ltd.		
	AO +	WO 03/077897 A1	09-25-2003	Cypress Bioscience, Inc.		
	AP +	WO 94/01095 A3	01-20-1994	Smith-Kline Beecham PLC		
	AQ +	WO98/50037	11-12-1998	Mitsubishi Chemical Corporation		X
	AL2 +	WO 2004/004734 A1	01-15-2004	Arachnova Therapeutics Ltd.		
	AM2 +	WO 01/41748 A2	06-14-2001	Novartis AG		
	AN2 +	WO 00/51583 A3	09-08-2000	Sepracor, Inc.		
	AO2 +	WO 00/51584 A3	09-08-2000	Sepracor, Inc.		
	AP2 +	EP 0 313 393 B1	03-16-1994	Yoshitomi Pharmaceutical Industries, Ltd.		

EXAMINER <i>Michel Gaffeo</i>	DATE CONSIDERED 24-Mar-06
----------------------------------	------------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
M6	AR	Milano, S, <i>et al.</i> , "The Piglet as a Suitable Animal Model for Studying the Delayed Phase of Cisplatin-Induced Emesis," <i>J. Pharmacol. Exp. Ther.</i> , 274(2): 951-961 (1995).
	AS	Prakash, C., <i>et al.</i> , "Tricyclic Antidepressants for Functional Nausea and Vomiting: Clinical Outcome in 37 Patients," <i>Dig. Dis. Sci.</i> , 43(9):1951-1956 (1998).
	AT	Center for Drug Evaluation and Research Application Number: 020623; Pharmacology Reviews; July 5, 1996.
	AU	Angel, I., <i>et al.</i> "Litoxetine: A Selective 5-HT Uptake Inhibitor with Concomitant 5-HT ₃ Receptor Antagonist and Antiemetic Properties," <i>Eur. J. Pharmacol.</i> , 232(2-3):139-145 (1993).
	AV	Crow, M.K., <i>et al.</i> "Management of Nausea and Vomiting," <i>Medical Oncology: A Comprehensive Review</i> , [Retrieved January 29, 2003] Retrieved from the Internet <URL:http://www.cancernetwork.com/textbook/morev41.htm>.
	AW	Depoortere, I., <i>et al.</i> , "Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis ¹ ," <i>J. Pharmacol. Exp. Ther.</i> , 294(3): 983-990 (2000).
	AX	Eguchi, J., <i>et al.</i> , "The Anxiolytic-Like Effect of MCI-225, A Selective NA Reuptake Inhibitor with 5-HT ₃ Receptor Antagonism," <i>Pharm. Biochem. and Behavior</i> , 68:677-683 (2001).
	AY	Fairweather, D.B., <i>et al.</i> , "The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers," <i>Br. J. Clin. Pharmacol.</i> , 40(2):119-125 (1995).
	AZ	Jin, J.G., <i>et al.</i> , "Propulsion in Guinea Pig Colon Induced by 5-Hydroxytryptamine (HT) Via 5-HT ₄ and 5-HT ₃ Receptors ¹ ," <i>J. Pharmacol. Exp. Ther.</i> , 288(1): 93-97 (1999).
	AR2	Kuver, R., <i>et al.</i> , "Nausea and Vomiting in Adolescents and Adults," <i>Nausea and Vomiting</i> , [Retrieved January 29, 2003] Retrieved from the Internet <URL:http://www.uwgi.org/cme/cmeCourseCD/ch_01/ch01txt.htm>
	AS2	Ladabaum, U. and Hasler, W.L., "Novel Approaches to the Treatment of Nausea and Vomiting," <i>Dig. Dis.</i> , 17(3): 125-132 (1999).
	AT2	Million, M., <i>et al.</i> , "Susceptibility of Lewis and Fischer Rats to Stress-induced Worsening of TNB-colitis: Protective Role of Brain CRF," <i>Amer. Phys. Soc.</i> , 276 (4 Pt 1): G1027-G1036 (1999).

EXAMINER 	DATE CONSIDERED 24. mar. 06
---	--------------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
	EXAMINER Unknown		CONFIRMATION NO. Unknown	GROUP Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
7/6	AU2 ✓	Prakash, C. and Clouse, R.E., "Cyclic Vomiting Syndrome in Adults: Clinical Features and Response to Tricyclic Antidepressants," <i>Am. J. Gastroenterol.</i> , 94(10): 2855-2860 (1999).
	AV2 ✓	Spiller, R., "Pharmacotherapy: Non-serotonergic Mechanisms" <i>Gut</i> , 51 (Suppl1): i87-90 (2002).
	AW2 ✓	Venkova, K., <i>et al.</i> , "Peripheral Activity of a New NK ₁ Receptor Antagonist TAK-637 in the Gastrointestinal Tract," <i>J. Pharmacol. Exp. Ther.</i> , 300(3): 1046-1052 (2002).
	AX2 ✓	Wood, J.D., <i>et al.</i> "Fundamentals of Neurogastroenterology," <i>Gut</i> 45(2):II6-II16 (1999).
	AY2 ✓	Butler, A., <i>et al.</i> , "Pharmacological Properties of GR38032F, a Novel Antagonist at 5-HT ₃ Receptors," <i>Br. J. Pharmacol.</i> , 94(2): 397-412 (1988).
	AR3 ✓	Sallan, S.E., <i>et al.</i> , "Antiemetics in Patients Receiving Chemotherapy for Cancer," <i>N. Eng. J. Med.</i> , 302(3): 135-138 (1980).
	AS3 ✓	Veyrat-Follet, C., <i>et al.</i> , "Physiology of Chemotherapy-Induced Emesis and Antiemetic Therapy," <i>Drugs</i> 53(2): 206-234 (1997).
	AT3 ✓	Morrow, G.R., <i>et al.</i> , "Progress in Reducing Nausea and Emesis," <i>Cancer</i> 76(3): 343-357 (1995).
	AU3 ✓	Eguchi, J., <i>et al.</i> , "Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride," <i>Arzneim.-Forschung/Drug Res.</i> , 47(12): 1337-1347 (1997).
	AV3 ✓	Kilpatrick, G., <i>et al.</i> , "Identification and Distribution of 5-HT ₃ Receptors in Rat Brain Using Radioligand Binding," <i>Nature</i> , 330: 746-748 (1987).
	AW3 ✓	Ito, C., <i>et al.</i> , "Effect of GK-128 [2-[(2-Methylimidazol-1-yl)- benzo[f]thiochromen-1-one Monohydrochloride Hemihydrate], a Selective 5-Hydroxytryptamine ₃ Receptor Antagonist, on Colonic Function in Rats," <i>J. Pharmacol. Exp. Ther.</i> , 280(1): 67-72 (1997).
	AX3 ✓	Owens, M. J., <i>et al.</i> , "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites," <i>J. Pharmacol. Exp. Ther.</i> , 283(3): 1305-1322 (1997).
	AY3 ✓	Béique, J.C., <i>et al.</i> , "Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters," <i>Eur. J. Pharmacol.</i> , 349(1): 129-132 (1998).

EXAMINER 	DATE CONSIDERED 24-mar-06
---	------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION March 1, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
m6	AZ3 /	Camilleri, M., "Serotonergic Modulation of Visceral Sensation: Lower Gut," <i>Gut</i> 51(1):81-86 (2002).
	AR4	Burns, M.J., "The Pharmacology and Toxicology of Reboxetine," <i>Int. J. Med. Toxicol.</i> 3(4):26 1-8 (2000).
	AS4	Bymaster, F.P., <i>et al.</i> , "Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters <i>In Vitro</i> and <i>In Vivo</i> , Human Serotonin Receptor Subtypes, and Other Neuronal Receptors," <i>Neuropsychopharmacology</i> , 25(6):871-880 (2001).
	AT4 /	Wong, E.H.F., <i>et al.</i> , "Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor," <i>Biol. Psychiatry</i> . 47(9): 818-829 (2000).
	AU4	LOTRONEX - Tablets, <i>Product Information</i> , GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).
	AV4	U.S. Provisional Application No. 60/364,531, filed 03-15-2002, entitled "Methods of Treating Visceral Pain Syndromes," by Rao <i>et al.</i> , priority document for WO 03/077897 A1 (Reference AO) and U.S. 2003/0203055 A1 (Reference AE3).
	AW4	GB 0304648.9, filed 02-28-2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperziny) Thieno[2,3-D] Pyrimidine," priority document for WO 2004/004734 A1 (Reference AL2).
	AX4	GB 0216027.3, filed July 10, 2002, entitled "New Therapeutic Use," priority document for WO 2004/004734 A1 (Reference AL2).

EXAMINER 	DATE CONSIDERED 24-Mar-06
---	------------------------------

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3506.1001-002APPLICATION NO.
10/757,981SUPPLEMENTAL INFORMATION DISCLOSURE
CITATION
IN AN APPLICATION

April 28, 2004

(Use several sheets if necessary)

FIRST NAMED INVENTOR
Steven B. LandauFILING DATE
January 13, 2004

EXAMINER

CONFIRMATION NO.
4256GROUP
1642

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
mb	AL3	WO 2004/019948 A1	03-11-2004	Arachnova Therapeutics, LTD.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

mb	AY4	GB 0316115.5, filed July 9, 2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl) Thieno [2, 3-D] Pyrimidine," priority document for WO 2004/019948 A1 (Reference AL3).
mb	AZ4	GB 0220064.0, filed August 29, 2002, entitled "New Therapeutic Use," priority document for WO 2004/019948 A1 (Reference AL3).

EXAMINER

Nicola Laffeo

DATE CONSIDERED

24-Mar-06

PTO-149 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION December 6, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1001-002	APPLICATION NO. 10/757,981	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004
	EXAMINER	CONFIRMATION NO. 4256	GROUP 1642

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
m6	AM3	WO 2004/058353 A3	07-15-2004	Amedis Pharmaceuticals, LTD.		

EXAMINER <i>Michael Gaffeo</i>	DATE CONSIDERED <i>24. Mar. 06</i>
--------------------------------	------------------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION January 24, 2005 (Use several sheets if necessary)		FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
		EXAMINER		CONFIRMATION NO. 4256	
				GROUP 1642	

[illegible]

EXAMINER	DATE CONSIDERED
<i>Michael Laffer</i>	<i>24. Mar. 06</i>

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3506.1001-002		APPLICATION NO. 10/757,981	
 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION February 24, 2006 (Use several sheets if necessary)		FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
		EXAMINER M. Graffeo		CONFIRMATION NO. 4256	
				GROUP 1614	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
m6	AI4	5,223,511	06-29-1993	Turconi <i>et al.</i>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
m6	ARS	Wu, Y.L. <i>et al.</i> , "Effects of Acute and Chronic Administration of MCI-225, a New Selective Noradrenaline Reuptake Inhibitor with 5-HT ₃ Receptor Blocking Action, on Extracellular Noradrenaline Levels in the Hypothalamus of Stressed Rats," <i>Japanese Journal of Pharmacol.</i> , 83:31-38 (2000).

EXAMINER <i>Michael Graffeo</i>	DATE CONSIDERED 24-mar-04
------------------------------------	------------------------------